文献速递湿疹皮炎与荨麻疹

环孢素A治疗儿童重度特应性皮炎:63例回顾性研究

Cyclosporine A for severe atopic dermatitis in children. efficacy and safety in a retrospective study of 63 patients.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2017-01-23

该回顾性研究纳入63例2009至2015年间接受环孢素A治疗的重度特应性皮炎患儿,评估疗效与安全性。治疗4周后35%疗效优、29%良、36%差;无嗜酸性粒细胞增多者应答更佳(P<0.05)。副作用常见但轻微,疗程较长者更常见(P<0.05);13例(20%)获得持续缓解(>6个月)。

要点

  • 环孢素A对多数重度特应性皮炎患儿起效快且有效。
  • 无嗜酸性粒细胞增多者治疗应答更佳(P<0.05)。
  • 副作用常见但轻微,需严格监测。

核心结论

  • 环孢素A对多数重度特应性皮炎患儿有效且起效迅速,部分患儿可获得持续缓解。
  • 环孢素A在儿童中耐受性似乎良好,但必须严格监测。

研究设计与样本

  • 回顾性研究,纳入2009年1月至2015年12月期间接受环孢素A治疗的重度特应性皮炎患儿63例。
  • 开始治疗时平均年龄8.4岁(±3.6),起始剂量中位数4.27(±0.61)mg/kg/天。

主要发现

  • 治疗4周后,35%的病例疗效优,29%良,36%差。
  • 无嗜酸性粒细胞增多的患者应答更好(P<0.05)。
  • 治疗时间中位数4.6个月(范围1.5-21.6)。
  • 副作用常见但轻微,在治疗时间较长的患者中更常见(P<0.05)。
  • 平均随访时间19.4个月(±12.7),13例(20%)观察到持续缓解(>6个月)。

临床怎么用

  • 环孢素A可用于儿童重度特应性皮炎,但需严格监测。
  • 治疗前嗜酸性粒细胞水平可能有助于预测应答。

局限性

  • 本研究为回顾性综述。
  • 随访时间有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cyclosporine A (CSA) is an immunosuppressant agent widely used in severe atopic dermatitis (AD). However, experience in children is limited. OBJECTIVES: To assess the efficacy and adverse events of CSA therapy in children. METHODS: Retrospective study of children with severe AD treated with CSA between January 2009 and December 2015. RESULTS: Data from 63 patients were collected. Mean age at the beginning of treatment was 8.4 years (±3.6). The median starting dose was 4.27 (±0.61) mg/kg/day. After 4 weeks of treatment, the outcome was excellent in 35% of cases, good in 29% and poor in 36% of the patients. The response was better in patients without eosinophilia (P < 0.05). The median duration of treatment was 4.6 months (range 1.5-21.6). Side-effects were frequent but mild, being more common in patients after longer treatment periods (P < 0.05). Mean time of follow-up was 19.4 months (±12.7). Prolonged remission (>6 months) was observed in 13 patients (20%). LIMITS: This is a retrospective review. The follow-up period is limited. CONCLUSIONS: Our data confirm that CSA is efficacious and acts rapidly in the majority of children with severe AD. CSA therapy can provide sustained remission in some patients. CSA seems to be well tolerated in children, but strict monitoring is mandatory.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Hernández-Martín A, Noguera-Morel L, Bernardino-Cuesta B, et al. Cyclosporine A for severe atopic dermatitis in children. efficacy and safety in a retrospective study of 63 patients. J Eur Acad Dermatol Venereol. 2017. PMID: 27896861. doi:10.1111/jdv.14066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。